Breathe BioMedical, a Canadian medical technology company developing a breath test for breast cancer, withdrew its plans for an initial public offering on Monday, citing market conditions. It had filed to raise $13 million by offering 2.6 million shares at a price range of $4 to $6.
The Moncton, Canada-based company was founded in 2005 and had planned to list on the Nasdaq under the symbol BRTH. Maxim Group LLC was set to be the sole bookrunner on the deal.
